How many drugs treat Minor Skin Wound Pain?

Drug Landscape tracks 10 marketed treatments for Minor Skin Wound Pain (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/minor-skin-wound-pain.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Minor Skin Wound Pain — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minor Skin Wound Pain (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Minor Skin Wound Pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tetracaine Hydrochloride	TETRACAINE	Alcon Labs	Ester Local Anesthetic	Sodium channel protein type 7 subunit alpha	2005-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Cortisporin	NEOMYCIN	Pfizer	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Bupivacain	Bupivacain	Sisli Hamidiye Etfal Training and Research Hospital		5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
xylocain	xylocain	Saint-Joseph University		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in Minor Skin Wound Pain
Pfizer · 3 drugs in Minor Skin Wound Pain
Bayer · 1 drug in Minor Skin Wound Pain
Fresenius Kabi · 1 drug in Minor Skin Wound Pain
Innocoll · 1 drug in Minor Skin Wound Pain
Saint-Joseph University · 1 drug in Minor Skin Wound Pain
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Minor Skin Wound Pain
University of Malaya · 1 drug in Minor Skin Wound Pain
Alcon Labs · 1 drug in Minor Skin Wound Pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Minor Skin Wound Pain:

Cite this brief

Drug Landscape (2026). Minor Skin Wound Pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/minor-skin-wound-pain. Accessed 2026-06-10.

Minor Skin Wound Pain full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing